[go: up one dir, main page]

ZA913725B - Method for preventing onset of restenosis after angioplasty employing pravastatin - Google Patents

Method for preventing onset of restenosis after angioplasty employing pravastatin

Info

Publication number
ZA913725B
ZA913725B ZA913725A ZA913725A ZA913725B ZA 913725 B ZA913725 B ZA 913725B ZA 913725 A ZA913725 A ZA 913725A ZA 913725 A ZA913725 A ZA 913725A ZA 913725 B ZA913725 B ZA 913725B
Authority
ZA
South Africa
Prior art keywords
pravastatin
angioplasty
restenosis
employing
preventing onset
Prior art date
Application number
ZA913725A
Other languages
English (en)
Inventor
Mark E Mcgovern
E Mcgovern Mark
Miguel A Ondetti
A Ondetti Miguel
Henry Y Pan
Y Pan Henry
Original Assignee
Squibb & Sons Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Squibb & Sons Inc filed Critical Squibb & Sons Inc
Publication of ZA913725B publication Critical patent/ZA913725B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ZA913725A 1990-05-31 1991-05-16 Method for preventing onset of restenosis after angioplasty employing pravastatin ZA913725B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/532,009 US5140012A (en) 1990-05-31 1990-05-31 Method for preventing onset of restenosis after angioplasty employing pravastatin

Publications (1)

Publication Number Publication Date
ZA913725B true ZA913725B (en) 1992-02-26

Family

ID=24120034

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA913725A ZA913725B (en) 1990-05-31 1991-05-16 Method for preventing onset of restenosis after angioplasty employing pravastatin

Country Status (10)

Country Link
US (1) US5140012A (xx)
EP (1) EP0459453A3 (xx)
JP (1) JPH04235915A (xx)
KR (1) KR910019630A (xx)
AU (1) AU646042B2 (xx)
CA (1) CA2041951A1 (xx)
HU (1) HUT58516A (xx)
IE (1) IE911780A1 (xx)
PT (1) PT97806A (xx)
ZA (1) ZA913725B (xx)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2042159A1 (en) * 1990-05-31 1991-12-01 Miguel A. Ondetti Method for preventing onset of restenosis after angioplasty employing an ace inhibitor
CA2042526A1 (en) * 1990-06-11 1991-12-12 Adeoye Y. Olukotun Method for preventing a second heart attack employing an hmg coa reductase inhibitor
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6306421B1 (en) 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6395494B1 (en) * 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US5770609A (en) * 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5595722A (en) * 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
EP0681475B1 (en) * 1993-01-28 2010-10-27 Boston Scientific Limited Therapeutic inhibitors of vascular smooth muscle cells
US6663881B2 (en) 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
CA2162586C (en) * 1993-05-13 2006-01-03 David J. Grainger Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
US5681278A (en) * 1994-06-23 1997-10-28 Cormedics Corp. Coronary vasculature treatment method
US5602110A (en) * 1994-08-31 1997-02-11 Case Western Reserve University Method and composition for treating cystic fibrosis
US6425881B1 (en) * 1994-10-05 2002-07-30 Nitrosystems, Inc. Therapeutic mixture useful in inhibiting lesion formation after vascular injury
EP0814799A1 (en) * 1995-03-20 1998-01-07 Allergan Use of retinoids for the manufacture of a medicament for the treatment of restenosis
AU6277396A (en) 1995-06-07 1996-12-30 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
US5900433A (en) * 1995-06-23 1999-05-04 Cormedics Corp. Vascular treatment method and apparatus
AU723315B2 (en) * 1996-09-18 2000-08-24 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
US6235706B1 (en) 1996-09-18 2001-05-22 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
US5902299A (en) * 1997-07-29 1999-05-11 Jayaraman; Swaminathan Cryotherapy method for reducing tissue injury after balloon angioplasty or stent implantation
US6180660B1 (en) 1997-08-26 2001-01-30 Merck & Co., Inc. Cholesterol-lowering therapy
US6034110A (en) * 1998-01-12 2000-03-07 Allergan Sales, Inc. Method for preventing onset of restenosis after angioplasty employing an RXR-specific retinoid and a PPARγ ligand
GB0001662D0 (en) 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
AU2007200367B2 (en) * 1999-02-06 2010-04-08 Astrazeneca Ab Use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy
SE9903028D0 (sv) * 1999-08-27 1999-08-27 Astra Ab New use
IL148127A0 (en) * 1999-08-30 2002-09-12 Aventis Pharma Gmbh Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
ATE382344T1 (de) * 1999-11-30 2008-01-15 Teva Gyogyszergyar Zartkoeruee Verfahren zur rückgewinnung von statinverbindungen aus einer fermentationsbrühe
EP1242051A4 (en) * 1999-12-14 2004-05-12 Biogal Gyogyszergyar NEW FORMS OF PRAVASTATIN SODIUM
US20020183383A1 (en) * 2001-02-27 2002-12-05 Rene Belder Pharmaceutical compositions
US6692772B2 (en) * 2001-07-18 2004-02-17 Cedars-Sinai Medical Center Prevention of in-stent thrombosis and complications after arterial angioplasty with stent placement using magnesium
US6576256B2 (en) 2001-08-28 2003-06-10 The Brigham And Women's Hospital, Inc. Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US6669955B2 (en) 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US20030077310A1 (en) 2001-10-22 2003-04-24 Chandrashekhar Pathak Stent coatings containing HMG-CoA reductase inhibitors
US7107198B2 (en) * 2001-11-02 2006-09-12 Sun Microsystems, Inc. Automatic generation of reduced-size circuit models including inductive interaction
DE202004020671U1 (de) * 2003-11-24 2005-12-08 Teva Gyogyszergyar Reszvenytarsasag Pravastatin
ES2282062T1 (es) 2004-06-04 2007-10-16 Teva Pharmaceutical Industries Ltd. Composicion farmaceutica que contiene irbesartan.
JP2007533663A (ja) * 2005-02-09 2007-11-22 テバ ジョジセルジャール ザ−トケルエン ムケド レ−スベニュタ−ルシャシャ−グ プラバスタチンナトリウムの製造方法
WO2006099244A1 (en) * 2005-03-11 2006-09-21 Hong Kong Nitric Oxide Limited Combination therapy for endothelial dysfunction, angina and diabetes
MX357919B (es) * 2009-03-13 2018-07-25 Nucitec Sa De Cv Composición farmacéutica para el tratamiento de la hipercolesterolemia.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK149080C (da) * 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
DE3536687A1 (de) * 1985-10-15 1987-04-16 Hoechst Ag Verfahren zur behandlung von atherosklerose, thrombose und der peripheren gefaesskrankheit
ZA896851B (en) * 1988-09-14 1990-06-27 Hoffmann La Roche Use of ace-inhibitors

Also Published As

Publication number Publication date
CA2041951A1 (en) 1991-12-01
AU646042B2 (en) 1994-02-03
AU7727591A (en) 1991-12-05
KR910019630A (ko) 1991-12-19
IE911780A1 (en) 1991-12-04
HU911815D0 (en) 1991-12-30
PT97806A (pt) 1992-02-28
US5140012A (en) 1992-08-18
JPH04235915A (ja) 1992-08-25
EP0459453A2 (en) 1991-12-04
HUT58516A (en) 1992-03-30
EP0459453A3 (en) 1993-02-24

Similar Documents

Publication Publication Date Title
ZA913725B (en) Method for preventing onset of restenosis after angioplasty employing pravastatin
HU912750D0 (en) Amido-3-pyrazole derivatives and processes for producing said compounds and phrmaceutical preparatives containing them
EP0612249A4 (en) Methods of inhibiting restenosis.
AU5537994A (en) Therapeutic treatment for inhibiting vascular restenosis
GB9122717D0 (en) Method of furniture manufacture
ZA913728B (en) Method for preventing onset of restenosis after angioplasty employing an ace inhibitor
GB9318000D0 (en) Inhibition of vascular restenosis
EP0487480A3 (en) Method for the manufacture of proteaseinhibitors from potato-fruitwater
HK113596A (en) Method of reducing access time
ZA92717B (en) Process for the shortening of the access time
GB2247171B (en) Method of disinfection
EP0595361A3 (en) Method of forming micropatterns
GB9021368D0 (en) Method of manufacture
GB2267822B (en) Cor or bed
GB9010672D0 (en) Method of forming absorbent articles
GB2241919B (en) Method of manufacture
RU1769863C (ru) Cпocoб haлoжehия xoлeдoxoдуoдehoahactomoзa
GB9111703D0 (en) Method of transsilylation
RU1833384C (ru) Cпocoб пoлучehия пpoизboдhыx cульфoлeha
SG75751A1 (en) Method of shortening the access time
AU1956692A (en) Method for inhibiting the development of body odors
RU1806865C (en) Method of needle-milling
RU1806867C (en) Method of roughing-conditioning needle-milling
RU1833722C (ru) Cпocoб лeчehия cиhдaktилии
BG96440A (en) Method for the furification of 8-phycoerythrin